中國華君(00377.HK)擬配發1200萬股 淨籌約1190萬港元
格隆匯6月23日丨中國華君(00377.HK)公吿,於2025年6月23日,公司(作為發行人)與認購人訂立認購協議。據此,認購人同意認購,而公司同意配發及發行合共1200萬股認購股份,認購價為每股認購股份1港元。
假設公司的已發行股本於本公吿日期至完成日期期間沒有任何變動,則認購股份佔公司於本公吿日期現有已發行股本約19.50%;每股認購股份的認購價1港元,等於(i)股份於2025年6月23日(即認購協議日期)為在聯交所所報收市價每股1港元;及(ii)股份於緊接認購協議日期前五個連續交易日股票在聯交所所報平均收市價每股1港元。扣除所有相關開支後,認購事項所得款項淨額預計約1190萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.